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Regulatory T cell markers are increased in chronically infected individuals with the hepatitis C virus (HCV), but to date, the
induction and maintenance of Tregs in HCV infection has not been clearly deﬁned. In this paper, we demonstrate that naturally
occurring viralvariants suppress T cell responses to cognate NS3358−375 in anantigen-speciﬁc manner.Of four archetypal variants,
S370P induced regulatory T cell markers in comparison to NS3358−375-stimulated CD4 T cells. Further, the addition of variant-
speciﬁc CD4 T cells back into a polyclonalculture in a dose-dependent manner inhibited the T cell response. These results suggest
thatHCVisabletoinduceantigen-speciﬁcregulatory TcellstosuppresstheantiviralTcell responseinanantigen-speciﬁcmanner,
thus contributing to a niche within the host that could be conducive to HCV persistence.
1.Introduction
Hepatitis C Virus (HCV) may evade the immune response
or impart a speciﬁc tolerance to itself to ensure its survival
in over 80% of infected individuals through mechanisms
such as, but not excusive to, viral escape, T-cell energy, and
induction of regulatory T cells (Treg).
RecentstudiesonhepatitisCvirus(HCV)havedescribed
an increase in Treg markers in cohorts ofchronically infected
patients when compared to resolved and noninfected indi-
viduals, possibly leading to viral persistence [1–7]. Although
these studiessuggest a correlationbetween Treg cell numbers
and HCV clearance, it has not been determined if Tregs
are induced in an antigen-speciﬁc manner or upregulated
to inhibit immunopathological damage associated with a
chronic infection.
There are two main subsets of Tregs: (I) thymically
selected natural Tregs (nTreg), which are phenotypically
deﬁned as CD4+ CD25hi Foxp3+, and (II) “inducible” Treg
cells, activated in the periphery, termed either Tr1 or Th3
deﬁned as secreting IL-10, TGFβ, and possibly IL-4 [8, 9].
A variety of markers are available to deﬁne Tregs, but the
mostgenerallyacceptedmarkeristheexpression ofForkhead
Box P3 (Foxp3). This expression positively correlates with
the development of Treg cells that have the capacity to
suppress the in vitro and in vivo proliferation and function
of eﬀector T cells [10–14]. Recent studies have found a
correlation between α-chain of IL7R (CD127) and Treg cells
[15]. Golden-Mason et al. also found a correlation between
CD127expressionand thevirological outcomeofacuteHCV
suggesting a relationship between HCV persistence and an
increase in Treg cells [16].
Previous work in our laboratory demonstrated a func-
tional induction of IL-10 in CD4 T cells in chronic HCV
subjects, indicative of inducible Treg cells, as opposed to
resolved HCV subjects which secreted IL-2 and IFNγ [17,
18].Further,screeningforimmunodominantepitopesinone
chronic HCV subject, using an array of synthetic peptides,
found an IFNγ and IL-2 producing epitope NS3358–375 show-
ingadistinctcytokineproﬁleincontrasttotherNS3protein-
stimulated PBMC [19]. In a longitudinal study tracking viral
variantsinachronicHCVsubject,weidentiﬁedviralvariants
consistent with selective immune pressure [20]. One variant,
S370P, was noted to be stable for over 2 years indicating2 Clinical and Developmental Immunology
selection and ﬁxation of this HCV viral isolate [20, 21].
Simple escape and redirection of the immune response
does not explain, however, the maintenance of an abundant
population of wild-type HCV sequences in infected patient’s
even years into an ongoing infection. This paradox is that
viral genomes persist in the presence of T cells, which should
be able to speciﬁcally recognize and help to clear virus
infected cells, and suggests there may be another level of
immunoregulation that is modulated by the viral infection
[22–26]. Based on these observations, we hypothesize that
a Treg population speciﬁcally suppresses the response of the
eﬀector T cells to the HCV antigens, and this Treg-mediated
suppressive activity is induced by naturally occurring viral
variants that accumulate mutations in an important viral
epitope recognized by helper T cells.
In the present study, we evaluated the role of naturally
occurring viral variantsinthe suppressionofTcell responses
to cognate NS3358–375 in vitro. Of four archetypal variants,
the S370P variant induced regulatory T cell markers in
comparison to NS3358–375-stimulated CD4 T cells. Further,
adding variant speciﬁc CD4 T cells back into a polyclonal
culture, in a dose-dependent manner, inhibited the T cell
response to cognate NS3358–375. These results suggest that
HCV may be able to induce regulatory T cells to suppress
the antiviral T cell response in an antigen-speciﬁc manner,
potentially creating a niche within the host that could be
conducive to HCV persistence.
2.Materialsand Methods
2.1. Patients. Blood was collected in acid citrate dextrose,
processed for PBMC isolation over lymphocyte separation
medium, and preserved in liquid nitrogen, as previously
described [27]. DNA was isolated from whole blood and
sent for HLA typing at the University of Utah (Table 1), and
the lymphocytes were incubatedwith various concentrations
of rNS3 to test for T cell responses. Quantitative RT-PCR
and HCV genotyping on all serum samples were sent to
ARUP laboratories (Salt Lake City, UT). All chronic HCV
subjects used in this study are genotype 1a (Table 1). If
the subjects had no detectable viral load, the samples were
screened for HCV antibodies by recombinant immunoblot
assay (RIBA)carried outat ARUPlaboratories. These studies
have been reviewed and approved by University of Utah
Institutional Review Board and the Medical College of
Wisconsin Institutional Review Board.
2.2. Cell Culture and Media. Culture of PBMC was in RPMI
1640 tissue-culture medium (BioWhittaker, Walkersville,
ME) supplemented with 25mM HEPES, 2mM L-glutamine,
100U/ml penicillin, 100ug/ml streptomycin, 1mM sodium
pyruvate, 5ug/ml gentamycin (all from Mediatech Cellgro,
Herndon, VA), 10U/ml heparin sodium (Fisher Scientiﬁc,
Pittsburgh, PA), and 10% pure human serum (Atlanta
Biologicals, Lawrenceville, GA). Cells were cultured in a
37◦C, 5% CO2 incubator.
2.3. Synthetic Peptides and Protein. In vitro, PBMCs were
stimulated with synthetic peptides representing one human
Table 1: HCV and HLA genotypes of HCV subjects. HCV and
HLA types of chronic and resolved subjects used in this study.
All subject’s PBMC were incubated with recombinant NS3 protein
(rNS3) in a dose-dependent manner using a proliferation assay to
detect T cell responses. All subjects were screened for HCV RNA by
quantitative PCR. In thecaseof resolved subjects, inwhich theyhad
no detectable viral load, a RIBA was performed to screen for HCV
antibodies. ∗subjects used for T cell proliferation assay in Figure 1.
Subject ID HCV status Genotype HLA-DR AB
∗ RLM 037 R − 1,15 +
∗ KML044 R − 9,15 +
∗ ZSS035 R − 1,15 +
∗ LEC028 R − 1,8 +
∗ KTJ010 R − 1,15 +
∗ BPB026 R − 3,15 +
∗ DRB012 R − 7,7 +
∗ JVP008 R − 15,15 +
JPZ061 R − 4,4 +
PH1127 R − 13,15 +
PH1079 R − 4,15 +
∗ AJG066 C 1A 1,8 ND
∗ KRW002 C 1A 8,14 ND
∗ MH065 C 1A 14,15 ND
∗ P.B3019 C 1A 15,7 ND
∗ NLM049 C 1A 11,13 ND
∗ CER014 C 1A 7,13 ND
∗ DRB051 C 1A 1,13 ND
∗ SSB007 C 1A 7,13 ND
RLW027 C 1A 4,15 ND
P.1022 NI − 8,10 −
P.1163 NI − 1,15 −
P.1078 NI − 9,13 −
P.1127 NI − 5,6 −
leukocyte antigen DR15 (HLA-DR15) restricted epitope
surrounding HCV NS3 amino acids 358–375 (aa 1384–
1401 of the HCV polyprotein). The three single amino acid
variants were identiﬁed in a chronic HCV patient (P.B3019),
and recombinant nonstructural protein 3 (rNS3) protein
was puriﬁed as previously described [17, 28]. Recombi-
nant H3 (A/Phillipines/1992) and H5 (A/Vietnam/2004)
were obtained from Protein Sciences. Peptides were syn-
thesized using Fmoc chemistry and HPLC puriﬁed, dis-
solved in a small amount of DMSO, and then adjusted to
1mg/ml stock solutions in RPMI 1640. Peptide sequences
were as follows: wild-type 358–375, VIKGGRHLIFCH-
SKKKCD; variant H369R, VIKGGRHLIFCRSKKKCD; vari-
ant S370P, VIKGGRHLIFCHPKKKCD; variant K371E,
VIKGGRHLIFCHSEKKCD.
2.4. T-Cell Proliferation Assay. To measure proliferative
responses of PBMC following stimulation with wild-type
peptide NS3358–375 and several variants, 1 × 105 PBMC
were plated in round-bottom 96—[29] incubated at 37◦C,
5% CO2 for either 4 or 6 days, as indicated, pulsedClinical and Developmental Immunology 3
Table 2:CD4+ andCD8+ TcellresponsestorNS3andH3Agsasshownasfrequency ofCFSElow andthetransformationofTcellproliferation
data. Frequency of CD4+ and CD8+ T cells in CFSE-labeled lymphocytes when stimulated with rNS3 and H3 at 1μg/ml for 7 days and
analyzed by ﬂow cytometry. On Day 7, the cells were stained with CD4 and CD8. The proliferative response was determined by the medium
for each subject. log10Δmax is the transformation of the T cell prolﬁeration data for each subject and the respective antigen stimulation.
Subject Medium NS3 H3
CD4 CD8 CD4 CD8 log10Δmax CD4 CD8 log10Δmax
RLM 037 R 0.97 1.49 6.97 7.1 4.4 1.49 4.91 0
KML044 R 0.29 0.53 4.06 10.7 4 0.27 0.63 0
ZSS035 R 0.6 0.95 4.12 2.65 4.2 3.73 1.85 4.1
LEC028 R 1.16 0.54 6 2.4 4 1.81 0.8 2
KTJ010 R 1.33 1.32 4.98 2.92 4 1.88 1.95 2.5
BPB026 R 0.4 0.29 1.58 1.12 3.2 0.42 0.22 2.7
DRB012 R 1.22 0.77 0.8 3.68 2.5 0.8 3.68 3.5
JVP008 R 0.4 0.46 2.61 4.07 3.2 0.8 0.47 3
JPZ061 R 1.34 1.76 1.1 1.41 3.3 1.15 1.3 0
AJG066 C 4.31 4.84 4.73 4.8 3.4 4.81 4.68 0
KRW002 C 4.79 4.6 5.29 5.19 3.8 5.43 4.75 3.5
MH065 C 6.31 7.21 6.97 7.29 3.6 6.6 7.3 3.2
NLM049 C 1.84 4.47 2.01 14.2 3.5 0.18 0.84 3.05
CER014 C 0.68 0.34 1.04 0.75 4 0.74 0.33 3
SSB007 C 22.7 29.1 23.8 31.5 3.9 23.1 28.1 0
RLW027 C 0.16 0.44 0.33 1.99 4.2 0.18 0.84 3.8
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Figure 1: Resolved HCV subjects have a signiﬁcantly higher T cell
response to rNS3 than chronic HCV subjects. PBMCs from both
resolved subjects (gray circle) (n = 8) and chronic (black triangle)
(n = 8) subjects (subjects used in Figure 1 are ∗ in Table 1)w e r e
individually incubated with rNS3 (1μg/ml) and H3 (3μg/ml), H5
(3μg/ml), and PHA (2μg/ml) for 7 days. All subjects were screened
in the same proliferation assay. As described in the results, the
algorithm: log10Δmax was used to transform the data [29]. The
P<. 05
∗ as determined by Student’s t-test.
overnight with 1μCi/well of titrated thymidine (3H-TdR),
and harvested onto glass ﬁber ﬁlters for measurement of
radiolabel incorporation by gas scintillation spectroscopy.
Results are presented as the mean ± SEM of at least tripli-
cate cultures (typically 6 wells/sample were analyzed), and
sampleswere comparedusing Student’sunpaired t-test. Data
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Figure 2: HCV subjects have an attenuated CD4+ T cell response
to rNS3. HCV chronic subjects (black triangle) (n = 7) (Table 2)
had a signiﬁcantly lower CD4 CFSElow response to rNS3 (1μg/ml)
in comparison to resolved subjects (gray circle) (n = 9) (Table 2).
There was no diﬀerence in the H3 (1μg/ml) response between
groups. The P<. 05
∗ as determined by Student’s t-test.
were considered signiﬁcant at P<. 05. Proliferation data
was transformed using a previously described algorithm:
log10Δcpm = log10[Xexp − Xexp][ 29].
2.5. Foxp3 Staining. PBMC were analyzed by ﬂow cytometry
to evaluate the frequency of Foxp3 in an expanding CD4+4 Clinical and Developmental Immunology
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Figure 3: Higher frequency of Foxp3+ cells in chronic HCV subjects in comparison to resolved HCV subjects. (a) Back gating analysis of %
Foxp3+ cells inCD4+ CD127− CFSElow cells. PBMCswere labeled with CFSEandthen stimulatedwitheither rNS3 (1μg/ml)orH3 (1μg/ml)
and incubated for 7 days. The ﬂuorescence minus one (FMO) plus isotype control for Foxp3 antibody was used to determine the gate for
Foxp3+ cells (upper panel). An example of PBMCstimulated with an antigen is shown in the lower panel. (b) Chronic HCV patients (n = 9)
have a signiﬁcantly higher percentage (∗P<. 05 as determined by Student’s t-test) of CD4+ CD127− CFSElow Foxp3+ expressing cells in
comparisonto resolved HCV subjects (n = 9), (Supplementary Table 2 ). Δ = [Experimental−Medium]. Noninfected subjects (n = 5) were
stimulated with the recombinant H3 antigen as a comparison (Supplementary Table 2).Clinical and Developmental Immunology 5
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Figure 4: PBMC proliferative responses to NS3358–375 peptide
variants. (a) HCV subject P.B3019 PBMC incubated for 3h with
peptide variants at 1μM then with the addition of 1μM wild-type
peptide NS3358–375 where indicated. On Day 4, proliferating cells
were labeled with1μCi 3H-TdR fortheﬁnal16hofincubation,and
cells were harvested for measurement of 3H-TdR incorporation on
Day 5. Results are shown in mean counts per minute (CPM) +/−
standard error of at least triplicate cultures. ∗P<. 05 as determined
by Student’s t-test. ∗∗P<. 005. Results are representative of greater
than 10 experiments.
T cell population when stimulated with various antigens in
bothHCVchronicandresolvedsubjects.Carboxyﬂuorescein
succinimidyl ester (CFSE) staining protocol was adapted
from Quah et al. [30]. Brieﬂy, 0.5μM CFSE was added
to PBMC in complete media + 10% PHS for 5min. at
37◦C, washed 3 times, and stimulated with the appropriate
antigen(s) for 7 days. Cultures were then stained with CD4-
Paciﬁc Blue, CD8-Amcyan, CD25-APC, and CD127-percp-
cy5.5 (BD Pharmingen, San Diego, CA) for 20min. at 4◦C
and then washed 2x with stain buﬀer (BD Pharmingen, San
Diego, CA). Using eBioscience Foxp3 staining kit, the cells
wereﬁxedandpermeabilizedfor1hrat4◦Candthenwashed
2x in permeabilization buﬀer. Normal rat serum was added
(2μl/100μl) for 15 minutes and then stained with Foxp3-
PE (eBioscience, San Diego, CA) for 1hr at 4◦C, washed
2x with stain buﬀer, and analyzed on a BD FACS Canto
II. To account for ﬂuorescence spill over and nonspeciﬁc
staining, weperformed ﬂuorescence-minus-one (FMO)with
isotype control. More speciﬁcally, FMO controls contain all
of the antibody conjugates used in the experiment except
one, with the addition of the appropriate isotype control of
the ﬂuorochrome initially excluded. This was performed for
each ﬂuorochrome and each unique culture condition. For
PH1127, the addition of IL-10 was added 3 hours after the
appropriate antigen was added to culture at 2ng/ml. Results
were compared using Student’s t-test. Flow cytometry data
analysis was performed using Flow Jo software (Tree Star).
2.6. Magnetic Cell Sorting. To deplete CD4+CD25+ Treg cells
from the PBMC, magnetically labeled microbeads were used
and selected for using an autoMACS Separator (Miltenyi
Biotec, Auburn, CA). First, non-CD4+ cells were labeled
by incubation with a cocktail of biotin-labeled antihuman
antibodies against CD8, CD14, CD16, CD19, CD36, CD56,
CD123, TCRγ/δ, and glycophorin A, followed by addition
of antibiotin microbeads, as recommended by the manu-
facturer of the CD4+CD25+ regulatory T cell isolation kit
(Miltenyi Biotec). The non-CD4+ cells were then depleted
with theautoMACSseparator, resuspended inculturemedia,
and set aside. CD25microbeadswere addedtotheremaining
CD4+ cell pool and positively selected with the autoMACS.
The resulting CD25-depleted CD4+ cells were pooled with
the non-CD4+ cells and cultured with peptides as described
above for proliferation assays.
2.7. Tetramer Staining. All tetramers were obtained from
the NIH tetramer facility at Emory University. PBMC
were stained immediately following thawing and washing.
The CD4+T cells speciﬁc for NS3358 were ampliﬁed by
stimulating PBMC from PB3019 with 1μMo fc o g n a t e
peptide and incubate the cells at 37◦C, 5% CO2 for 7
days. The cells were then sorted at the University of Utah
cell-sorting core facility. PBMCs were stained with CD4-
APC (BD bioscience) and sorted under sterile conditions
by gating on CD4+ CFSElow cells. The sorted cells were
expanded with CD3/CD28 Dynal beads (Invitrogen) and
10U/ml of rIL-2 (BD Bioscience) at 37◦C, 5% CO2.P r i o rt o
staining with either wild-type 358–375-Phycoerythrin (PE),
or variant H369R-Allophycocyanin (APC), variant S370P-
APC,orvariantK371E-APCtetramers, theCD3/CD28beads
were magnetically removed from the cultures, and the cells
were stained with 2μg/ml of tetramer at 37◦Cf o r1 h ri n
complete media plus 10%PHS. Extracellular surface staining
was performed by adding 7-AAD cell viability probe, CD4-
paciﬁc blue (BD bioscience), CD3-Amcyan (BD bioscience),
and CD8-FITC (eBioscience). Negative controls consisted of
staining cells with nonspeciﬁc peptide, CLIP-DR15 tetramer,
labeled with either -PE label or -APC, respectively, which
were performed with each experiment and noninfected
individuals.
2.8.TetramerDepletionandAddBackAssays. Tetramerstain-
ing (10μg/ml) with the wild-type 358–375-Phycoerythrin
(PE),variantH369R-Allophycocyanin(APC),variantS370P-
APC, and variant K371E-APC were incubated with PBMC
(1×106 cells/50μl)ina96roundwellbottomplatefor90min
at RT temperature in the dark. The cells were washed, and
M A C Sb e a d ss p e c i ﬁ cf o re i t h e ra n t i - A P Co ra n t i - P Ew e r e
incubated with their respective tetramer for 15 minutes at
4◦C. The cells were washed, and then applied to MS MACS
column and tetramer depleted. Tetramer-positive cells were
then collected and washed. Next, the cells were washed 2×
in complete media + 10%PHS and then stimulated with the
appropriate antigens. In the appropriate cultures, tetramer-
positive cells were added to cultures in a dose-dependent
manner based on volume. A CLIP-loaded tetramer for both6 Clinical and Developmental Immunology
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Figure 5: Increased Foxp3 expression in an antigen-speciﬁc manner by variant S370P stimulated PBMC from chronic P.B3019. (a)
Representative ﬂow plots of CFSElow Foxp3+ cells from lymphocytes that were CD4+ CD127− (gating scheme Figure 3(a))s t i m u l a t e dw i t h
the indicated antigens at 1μM for 7 days. Peptide added to PBMC cultures is listed above the plot, and the percentages are the percent of
CD4+CD127−CFSElow cells. (b) Variant S370P (x = 81.8 ± SEM 5.7) stimulated PBMC signiﬁcantly increases the expression of Foxp3 in
CD4+CD127−CFSElow cells above the medium background (x = 55.73 ±SEM 2.57) for P.B3019. ∗P<. 05 as determined by Student’s t-test.Clinical and Developmental Immunology 7
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Figure 6: PBMC proliferative responses to NS3358–375 peptide
variants and mixes with wild-type peptide in cultures depleted
of CD4+CD25+ Treg cells. Subject 3019 total or Treg-depleted
PBMC were stimulated with peptide variants and measured 3H-
TdR-uptake. Results are mean counts of six wells each +/− SEM,
representative of three independent experiments. Gray bar, indi-
vidual peptide; stripped bars, CD4+CD25+ Treg-depleted PMBC.
∗P<. 05 as determined by Student’s t-test. ∗∗P<. 005.
PE and APC ﬂuorochromes were used as a control for
nonspeciﬁc staining.
3.Results
3.1. Foxp3 Expression in Chronic and Resolved HCV Subjects.
To compare chronic (n = 8 )a n dr e s o l v e d( n = 8)
HCV subjects’ T cell responses to rNS3, we measured
recall responses in vitro (Table 1 and Figure 1). Responders
were considered as those giving a response greater than 2
SDs above Xbkg. Figure 1 shows the medium background
s u b t r a c t e df r o mt h et r i p l i c a t er e s p o n s et og i v eaΔcpm value
plotted on a log scale, described in methods. As controls,
we included H3 (3μg/ml), H5 (3μg/ml), and PHA (2μg/ml)
(Figure 1). Each subject responded to PHA, and there was
no statistically signiﬁcant diﬀerence in the T cell response
for any of the control antigen s .H o w e v e r ,r N S 3i n d u c e dT
cell proliferation in chronic subjects (3.1 SEM ± 0.17) was
signiﬁcantly attenuated (P<. 05) compared to resolved
subjects (4.01 SEM ± 0.15). Similarly, ﬂow cytometric
analysis of proliferating T cells stained with CFSE (Figure 2)
reveals a signiﬁcantly (P<. 05) attenuated CD4+ Tc e l l
response in chronic HCV subjects (0.42 SEM ± 0.15) (n =
7) when compared to the resolved subjects (2.9 SEM ±
0.68) (n = 9) (Figure 2, Table 2). Although the CD8+ T
cell response was not statistically signiﬁcantly lower in the
chronic compared to resolved T cell subjects, a trend towards
lower CD8+ T cell response was evident in the chronic (1.8
SEM ± 1.8) compared to resolved (3.1 ± 0.7) (Figure 2,
Table 2).
TodetermineifCD127(IL-7Rα)correlatedwithchronic-
ity as determined by other laboratories [16], we used ﬂow
cytometricanalyses toanalyze theCD127expression onboth
CD4+ andCD8+ Tcellsinchronic(n = 7),resolved(n = 10),
and noninfected (NI) (n = 5) on Day 7 poststimulation
antigen stimulation (see Table 1 in Supplementary Materials
available online at doi:10.1155/2011/806061). Further, the
upregulation of CD127 on CD4+ T cells has been shown to
inversely correlate with Tregs in humans, and the negative
selection of CD127 can be used as an accurate extracellular
biomarker of Tregs as opposed to CD25 [15]. The nonin-
fected subjects had a signiﬁcantly (P<. 05) lower expression
of CD127− (26 SEM ± 4.1) cells in comparison to resolved
(40 SEM ± 2.8) and chronic (62.2 SEM ± 4.2) subjects
(Supplementary Table 1) and the levels remained relatively
consistent regardless of antigen stimulation. To test if HCV
was able to induce antigen-speciﬁc Tregs, we analyzed CFSE
dilution assays staining for CD4+ CD127− CFSElow cells at
7 days poststimulation (Figure 3(a)). Chronic HCV subjects
(16.6 SEM ± 5.2) had a signiﬁcantly higher expression of
F o x p 3i na n t i g e n - s p e c i ﬁ cC D 4Tc e l l st h a tw e r eC D 1 2 7 − (0
SEM ± 3.7) or negative controls stimulated with H3 (0 SEM
± 2.4) (Figure 3(b), Supplementary Table 2). These results
suggest antigen stimulation with rNS3 causes expansion of
regulatory T cells at a higher frequency in chronic HCV
subjects compared to resolved HCV subjects.
3.2. Synthetic Peptide-Mix Experiments. Previous work in
our laboratory identiﬁed Th1 epitopes in a single HCV
chronic subject and further characterized the viral variants
that arose in one of the Th1 epitopes identiﬁed, NS3358–375
[21, 31]. Further, these variants were found not only to
escape immune detection but were able to shift the cytokine
proﬁle from a Th1 cytokine pattern, which is correlated
with viral clearance, to either a Th2 or Treg viral persisting
response, respectively [21, 31]. Because variants and “wild-
type” viruses exist together in the circulation, we attempted
to simulate in vivo conditions by using what we have termed
peptide-mixing experiments in cell-culture assays. Extensive
work was performed using P.B3019 PBMCs to test the eﬀect
of various peptide concentrations and kinetics that each
of the variants had on the cognate T-cell response (data
not shown). It should be noted that our approach is very
similar to previously described antagonism assays, with the
exception being that we used polyclonal PBMCs instead of
T-cell clones[32]. Our preliminary experiments showed that
the proliferative response of PBMC preincubated with 1μM
of variant peptide 3 hours prior to the addition of 1μM
NS3358–375 peptide was inhibited (data not shown), which is
consistent with an antagonism model. Further, if NS3358–375
peptide was added either before or at the same time as the
variant peptide, there was no eﬀect on NS3358–375 Tc e l l
proliferation (data not shown). Therefore, in subsequent
experiments, variant peptide remained after the addition of
the NS3358–375 peptide and cultures were incubated at 37◦C
at 5% CO2 f o re i t h e r5o r7d a y st h e np u l s e dw i t h3H-
Thymidine for the last 16–18hrs. Cultures incubated with
single peptide variants alone failed to stimulate as well as the8 Clinical and Developmental Immunology
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Figure 7: DRB1∗1501 MHC class II variant and cognate tetramers are able to bind to CD4+ T-cells from multiple patients. PBMCs from
a noninfected (P1163), chronic (P.B3019), and resolved (JVP008) were individually stained with DR15 MHC class II tetramers (2μg/ml).
P.1163 is a noninfected DR15 subject and was used as a control to test for nonspeciﬁc labeling of each DR15 tetramer (ﬁrst column). DR15-
CLIP-APC and -PE tetramers were used as a control for each experiment (bottom two rows).
wild-type NS3358–375 peptide (Figure 4). Further, peptide-
mixcultures(variant(s)+wildtype)showedreducedlevelsof
proliferation relative to those with NS3358–375 peptide alone
(Figure 4).
3.3. Flow Cytometric Analysis of Inducible Tregs. To deter-
mine if variant S370P was able to induce Tregs in an
antigen-speciﬁc manner, we stimulated P.B3019 PBMC with
the indicated antigens, incubated the cells for 7 days, and
analyzed the phenotype of proliferating cells in a CFSE
dilution assay (Figure 3(a)). The induction of Foxp3 by
variants H369R and K371E was not signiﬁcantly higher in
comparison to NS3358 peptide stimulated culturesbut S370P
induced a large population of Foxp3+ cells (Figure 5(a)).
Multiple experiments were performed using S370P because
S370P was the only variant that was stable for over 2 years in
PB3019(Figure 5(b)).PBMCfromPB3019(n = 3)increased
Foxp3 expression (P<. 05) when stimulated with S370P
(x = 81.8%) (Figure 5(b)) in comparison to unstimulated
culture (x = 55.73%) (Figure 5(b)).
3.4. CD4+CD25+ Treg Depletion. To determine if naturally
occurring variants inhibit T cell proliferation, we used com-
mercially available CD4+CD25+ regulatory T cell isolation
kit to deplete CD4+CD25+ T cells from a PBMC pool prior
to stimulation with the NS3358–375 and variant peptides
(Figure 6). Depletion of CD4+CD25+ Tregs enhanced the
proliferation of T cells in response to NS3358–375 peptide
(Figure 6, gray versus black stripped bars, resp.). Further-
more, stimulation with the K371E variant alone in cultures
depleted of CD4+CD25+ Treg cells led to an increase in the
proliferation level, suggesting that at least one mechanism by
which the peptide variants suppress eﬀector T cell responses
is through the induction of Tregs.
3.5. MHC Class II Tetramer Staining Using Multiple HCV
Subjects. To determine if DR15 MHC class II tetramers
loaded with NS3358–375, or the variant peptides H369R,
S370P,and K371E,were able tobind toCD4+ Tcells, PBMCs
from multiple HCV subjects were stained for antigen-
speciﬁcTcells(Figure 7).P.1163,anoninfectedDR15subject
(Table 1) ,w a su s e da sac o n t r o l .A l s o ,D R 1 5C L I P - P Ea n d
-APC tetramers were used as controls in each experiment
(Figure 7, bottom two rows). Both P.B3019 (chronic infec-
tion) and JVP008 (resolved infection) had detectable DR15-
restriced CD4+ Tcellswithvaryingaviditiesforthetetramers
(Figure 7). Finding HCV-speciﬁc T cells in more than one
HCV subject suggests that this is not an idiosyncratic
phenomenonalthough largernumbers ofpatientsneed to be
studied in order to determine whether our results reﬂect a
more general observation.
3.6. MHC Class II Tetramer Depletion Assays. To test the
speciﬁcity of variant-induced suppression, PBMCs were
stained with variant-loaded tetramers, and magnetic beads
were used to remove tetramer-positive T cells; such depleted
PBMC cultures were subsequently stimulated with peptides
as indicated (Figures 8(a)–8(d)). Both H369R and K371E
tetramer-depleted cultures responded better to NS3358–375
peptide in comparison to the nondepleted cultures (Figures
8(a), 8(c)). Although S370P tetramer depleted cultures did
not have a statistically signiﬁcantly higher T cell response
in comparison to nondepleted cultures, S370P-depleted
cultures consistently showed an enhanced T cell response to
NS3358–375 (Figure 8(b)). Adding-back tetramer positive cells
to depleted cultures restored suppression (Figures 8(a)–8(c),
black bars). Using a nonspeciﬁc control tetramer showed
no eﬀect on T cell responses to the NS3358–375 peptide
(Figure 8(d)). The results indicate that tetramer depletion of
variant-speciﬁc T cells enhances T cell proliferative response
to the NS3358–375 cognate peptide in an antigen speciﬁc
manner.
3.7. MHC Class II Tetramer Add-Back Assays. To address the
potency of variant-speciﬁc T cells to suppress the cognate
T cell response, we added variant tetramer positive cells
back into PBMC culture stimulated with NS3358–375 peptide.
After tetramer depletion, PBMC cultures were stimulated
with NS3358–375 peptide (Figure 9(a)). Because of variability
in levels of proliferation, responses in the presence of
each variant were normalized to WT alone; note the eﬀect
of dilution upon responsiveness at 25% (vol/vol). T cell
responses in the restored presence of all variant-speciﬁc
T-cells were suppressed in a dose-dependent manner. To10 Clinical and Developmental Immunology
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Figure 8: Tetramer depletion of T cells speciﬁc for variant peptides restores T cell proliferative response to cognate NS3358–375. (a–c) Variant
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Figure 9: Tetramer-positive cells suppress T cell proliferation in a dose-dependent manner. P.B3019 PBMCs were stained with pooled
variantsofH369R,S370P,andK371E(black),CLIP(lightgray),orWTNS3358–375 (darkgray)and removed by bead depletion. After tetramer
depletion, the cultures were stimulated with NS3358–375 peptide. Tetramer-positive cells were volumetrically added back into culture with
P.B3019 NS3358–375 stimulated PBMCs. Data is representative of percent response to NS3358–375 stimulated PBMCs depleted with indicated
tetramer(s) (WT alone) and set to 100%. Controls were CLIP (light gray) and NS3358–375 (dark gray). (b) PB3019 PBMC cultures were
stimulated with indicated peptide(s) with each tetramer added at 10μg/ml and incubated for 7 days.
control for nonspeciﬁc depletion and suppression, we used
a CLIP-loaded tetramer, which resulted in no eﬀect on the
T cell response. Depletion of PBMC cultures with NS3358–375
tetramer and subsequent add-back of NS3358–375-speciﬁc T
cells actually enhanced proliferation at lower volumes. This
result is not due to toxicity because the same concentration
of tetramer (10μg/ml) added into culture along with the
respective peptide(s) at 1μM resulted in no inhibition of
T cell proliferation (Figure 9(b)). We conclude from these
experiments that variant-tetramer-positive T-cells are able to
suppress T cell proliferation to wild type NS3358–375 in vitro.
To our knowledgethis is theﬁrst demonstration ofwhat may
be antigen-speciﬁc regulatory T cells.
3.8. MHC Class II Tetramer Staining of NS3358–375-Speciﬁc
CD4+ T Cells. To extend our observation that variant-
speciﬁc T cells are able to bind to cells that are speciﬁc for
the cognate peptide in a somewhat larger cohort of subjects,
we ampliﬁed CD4+ T-cells speciﬁc for NS3358–375 peptide.
PBMCs from HLA-DR15 subjects (Table 1) were prelabeled
with(0.5μM)CFSEandstimulatedwithNS3358–375 synthetic
peptide for 7 days. The CD4+ CFSElow cells were sorted,
expanded with CD3/CD28 beads, and stained with tetramer
following removal of beads. All cultures were >99% CD4+
as determined by ﬂow cytometry (data not shown). Trop
no. 20 (HLA-DR1/3) are CFSElow CD4+ T cells expanded
in the same manner except that shrimp tropomyosin was
substituted for NS3358–375 and served as an additional nega-
tive control (Figure 10, ﬁrst column). Nonspeciﬁc tetramer
(CLIP)-APC and -PE were also used as controls in each
experiment (Figure 10). As might be expected, NS3358 and
variant MHC class II tetramers stain PB3019, PH1127, and
PH1079 CD4+ antigen-speciﬁc T cells all of which share or
require the HLA-DR15 restriction element. Thus, tetramers
loaded with either cognate or variant peptides are likely to
bind overlapping subsets of T-cells found in PBMC from
multiple subjects.
4.Discussion
We demonstrate in vitro induction of regulatory T cells
capable of suppressing antigen-speciﬁc T cell responses. We
postulated that previously deﬁned viral variants in a Th1
epitope couldbe responsible for the inductionof Tregs based
on the cytokine shift and attenuated T cell response [17].
Further, chronically infected subjects exhibited signiﬁcantly
lower T cell responses in comparison to resolved subjects.
These attenuated T cell responses correlated with the induc-
tion of the Treg lineage-speciﬁc markers in proliferating T
cells speciﬁc for rNS3.
Although Fuller et al. [33] identiﬁed and tracked HCV
NS3 viral variants in MHC class II-restricted epitopes in an
infected chimpanzees, similar to our previous work [20], but
it was not clear if the viral variants were able to aﬀect the
T cell response to cognate peptide. Our study demonstrated
that viral variants attenuated T cell responses to cognate
peptide and not unrelated peptide. Further, the speciﬁc
variant, S370P, induced Foxp3 in an antigen-speciﬁc manner
in a chronic HCV patient. In an eﬀort to generalize our
ﬁnding from one chronic subject, we were able to detect12 Clinical and Developmental Immunology
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Figure 10: MHC class II tetramers are able to stain NS3358–375 antigen-speciﬁc CD4+ T cells. PBMC from PB3019, PH1127, and PH1079
were prestained with CFSE and stimulated with NS3358–375 synthetic peptide for 7 days. The CFSElow cells were sorted and then stained with
each tetramer. The cells are >99% CD4+ as determined by ﬂow cytometry (data not shown). Trop no. 20 are CFSElow tropomysoin-speciﬁc
CD4+ T cells expanded by the same procedure asNS3358–375.Trop #20 wasused to control fortetramer speciﬁcity (ﬁrstcolumn).Nonspeciﬁc
tetramer (CLIP) was used for each experiment (bottom 2 panels). NS3358 and variant MHC class II tetramers stain PB3019, PH1127, and
PH1079 CD4+ CFSElow T cells. Not Tested (NT). Tetramer used is labeled on the right.
variant-speciﬁc T cells in multiple HLA-matched subjects.
The ability to detect the wild-type positive T cells along with
variant-speciﬁc T cells suggests that the mechanism of Treg
induction by naturally occurring epitope variant is likely
not exclusive to one chronically infected individual, albeit
the functional studies, though cumbersome, now need to be
doneinalargercohortofchronicandresolvedHCVpatients.
Previous studies had found that depletion of
CD4+CD25+ cells enhanced HCV-speciﬁc T cell response
to HCV antigens; however, these studies also described
enhanced T cell response to control antigens from Epstein-
Bar Virus (EBV), Cytomegalovirus (CMV), and inﬂuenza
indicating that the depletion of this subset of cells is not
speciﬁc for HCV [4, 34]. Depletion of CD4+CD25+ cells
restored PBMC proliferative responses to NS3358–375 to levels
that matched or exceeded those in the nondepleted PBMC
cultures that were preincubated with variant peptide. An
increase in the level of proliferation induced by variant
K371E alone following CD4+CD25+ cell depletion implied
a suppressive role for CD4+CD25+ Treg cells. These results
suggest that nonspeciﬁc depletion of Tregs enhanced T cell
proliferation.
Compelling evidenceforHCV-speciﬁcTregs byEbinuma
et al. [35]i d e n t i ﬁ e dC D 4 +CD25+ Foxp3+ MHC class II
tetramer positive cells in peripheral blood of HCV patients.
Further, Heeg et al. [7] performed a longitudinal study
using MHC class II tetramer staining to track HCV-
speciﬁc CD4+ Foxp3+ T cells during the course of HCV
infection in a cohort of patients. Although Heeg’s study
did not ﬁnd a correlation between an increase in Foxp3
expression and viremia, they did observe an attenuated
antigen-speciﬁc T cell proliferative response and lowered
IFNγ secretion in MHC class II tetramer positive cells.
These studies did not identify viral variants arising in
the epitopes analyzed, therefore, giving no indication if
viral variants could have an eﬀect on the cognate T cell
response [7, 35]. Depleting HCV-speciﬁc T cells that bind
to MHC class II variant tetramers, we found an enhanced
T cell proliferative response to NS3358–375 peptide and a
restoration of suppression when the variant-speciﬁc T cells
were added back. Although the depletion of S370P tetramer
positive cells did not signiﬁcantly enhance the proliferative
response over the nondepleted culture, the variant tetramer
depletion results suggest that the avidity of the tetramers
for NS3358–375-T cells are diﬀerent, leading us to hypothesize
that these variants could be acting as altered peptide ligands.
Consistent with this, K371E had a higher T cell response
when CD4+CD25+ cells and K371E tetramer positive cells
were removed indicating that this variant might aﬀect yet
ad i ﬀerent subset of cells. Further, adding variant tetramer
positive cells back into NS3358–375 stimulated cultures had
a dose-dependent suppressive eﬀect, suggestive of Tregs.
Taken together, our results suggest antigen-speciﬁc Tregs are
responsibleforsuppressionofaneﬀectorTcellresponse,and
we believe that a possible mechanism for this phenomenon
is that Hepatitis C viral variants may act as APLs to induce
Tregs. Previous [21, 36] and current work in our laboratory
clearlydemonstrates thatviral variants are abletoantagonize
cloned T cells speciﬁc for NS3358–375.F u r t h e r ,t h ev a r i a n t
peptides loaded onto MHC class II have diﬀerent avidities
for T cells that are speciﬁc for NS3358–375, which suggests
that these variants are acting as naturally occurring altered
peptide ligands (paper in preparation).
It has been observed that wild-type HCV sequences
remain stable in humans and chimpanzees even years into
an ongoing infection [2, 31, 33, 37]. We have shown that
approximately 80% of the circulating virus has “wild-type”
1A sequence [21, 31]. Interestingly, the S370P variant was
found in two isolates separated by 2 years, the variation
has not impacted viral ﬁtness negatively, yet its frequency
seems not to have increased with time as might be expected
with other escape models. Indeed, of all variants within the
NS3358–375 epitope tested to date, none has lost the ability to
bind the DR15 class II restriction element, which is contrary
toaclassicevasionescapemodel[38].ThefactthatHCVepi-
tope variants seem to induce a functional unresponsiveness
in peripheralT cellsimpliesaradically diﬀerentviral strategy
as well host-related immunopathogenesis. HCV seems to
have developed the ability to induce a speciﬁc tolerance to
itself by exploiting natural mechanisms that operate within14 Clinical and Developmental Immunology
the host. Our data suggest the hypothesis that viral mutation
leads to APL that blunts speciﬁc helper T cell responses,
which thereby attenuates the usual eﬀector mechanisms
requisite for antibody and killer T cell induction.
5.Conclusion
In conclusion, we have shown for the ﬁrst time that variants
of an HCV immunodominant epitope, which arose during
chronic infection in a human, induced Foxp3 expression
in an antigen-speciﬁc manner and had a dose-dependent
suppressive eﬀect in vitro, perhaps reﬂective of regulatory
T cells. While the number of individuals studied to this
point is small, we know that such variation occurs in
other individuals and applies to the cytotoxic eﬀector arm
of the immune response as well [39]; notably, this latter
study was performed in an HLA-DR15-positive subject.
Therefore, our in vitro results imply that selective immune
driven viral variants do not “escape” immune detection,
similar to observations by Fuller et al. [33], but rather they
avoid the consequences of immune recognition by inducing
antigen-speciﬁcTregswhichinturnprovide“immunological
cover” for wild-type viral sequences including those that
contain the NS3358–375 epitope, which should otherwise be
recognized, provide eﬀective T cell help such that virus can
be appropriatelyeliminated. Ourresults donot opposeother
mechanisms for viral persistence, but may act in concert to
subvert the adaptive immune response to HCV.
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